Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Critical Therapeutics.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Critical Therapeutics
ClinicalTrials.gov Identifier:
NCT00098358
First received: December 7, 2004
Last updated: February 5, 2007
Last verified: February 2007

December 7, 2004
February 5, 2007
November 2004
Not Provided
Change in number of inflammatory lesions
Same as current
Complete list of historical versions of study NCT00098358 on ClinicalTrials.gov Archive Site
  • Physician's global assessment scale
  • Change in number of non-inflammatory lesions
  • Change in total numbers of lesions
  • Change in sebum production
Same as current
Not Provided
Not Provided
 
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris

Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Acne Vulgaris
Drug: Zileuton
Not Provided
Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, Camera E, Cunliffe WJ. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol. 2003 May;139(5):668-70. No abstract available.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
90
May 2005
Not Provided

Inclusion Criteria:

  • Moderate to severe facial acne vulgaris
  • 20 to 60 facial inflammatory lesions
  • 10 to 200 facial non-inflammatory lesions
  • No more than 3 facial nodular cystic lesions

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Use of systemic or topical acne therapy within 14 days of study
  • Use of systemic retinoids within past 2 years
  • Skin diseases that interfere with acne counts
  • Active liver disease
  • Screening elevations in liver function tests
  • Positive serology for hepatitis B or C
  • Use of theophylline, warfarin, or propranolol within 7 days of study
  • Use of Singulair or Accolate within 14 days of study
  • Female patients who are pregnant or nursing
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00098358
CTI-02-C04-201
Not Provided
Not Provided
Critical Therapeutics
Not Provided
Study Director: Walter Newman, Ph.D. Critical Therapeutics
Critical Therapeutics
February 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP